News | July 09, 2013

Diastolic Dysfunction Can Be Targeted to Lower Congestive Heart Failure Readmissions

Researchers analyzed nearly 2,000 congestive heart failure patients

July 9, 2013 — Researchers have announced the results of a study which shows that among patients readmitted for congestive heart failure (CHF), a high E/e’ (a measure of elevated left ventricle filling pressure via ultrasound) at admission is significantly associated with higher 30-day readmission rates.  Focusing on lowering elevated E/e’ levels will be important to control healthcare costs and to reduce the high rates of morbidity and mortality in this patient population.

“We are happy to report that we now have some clear indicators on who might be at most risk of being readmitted in this patient population,” said Manoj Bhandari, M.D., an investigator on the study.

Bhandari and his colleagues analyzed 1,907 CHF patients using echocardiography to check the predictive nature of various measurements and the E/e’ was found to be independently associated with higher readmission rates.

The study, "High Admission E/e’ Is Independently Associated With Higher 30-day Congestive Heart Failure Readmission Rate," was a poster presentation at the 2013 American Society of Echocardiography (ASE) Annual Scientific Sessions.

For more information: www.asecho.org


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now